Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show07.01.2026 - 2Federal judge upholds Hawaii's new climate change tax on cruise passengers24.12.2025
- 3Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines26.12.2025
- 4Wedding trip Objections in the US01.01.1
- 5Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics15.11.2025
- Solid Living Tips: Experiences from a Wellness Fan
- Email Promoting Instruments for Compelling Efforts
- 'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- Authentic Urban areas: Rich Legacy and Lively Societies
- $2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- Vote In favor of Your Favored Pet Consideration Administration
- Banks for High Fixed Store Rates: Amplify Your Reserve funds
